1月16日,翰宇药业发布公告称:公司与一家客户签订了合同,涉及采购金额1.8亿元的GLP-1原料药。因为交易双方有保密要求,因此翰宇药业没有披露到底卖给了谁。但是翰宇药业透露:最近三年与对方有过类似交易,2025年就有7595.5万元的交易额。翰宇药业的核心业务聚焦于多肽制剂、原料药、小核酸与CRDMO四大板块,原料药业务包括司美格鲁肽(化学合成)、司美格鲁肽(半重组)、利拉鲁肽等。因此外界推测,...
Source Link1月16日,翰宇药业发布公告称:公司与一家客户签订了合同,涉及采购金额1.8亿元的GLP-1原料药。因为交易双方有保密要求,因此翰宇药业没有披露到底卖给了谁。但是翰宇药业透露:最近三年与对方有过类似交易,2025年就有7595.5万元的交易额。翰宇药业的核心业务聚焦于多肽制剂、原料药、小核酸与CRDMO四大板块,原料药业务包括司美格鲁肽(化学合成)、司美格鲁肽(半重组)、利拉鲁肽等。因此外界推测,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.